



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

**Gender-dependent difference in the  
effect of metformin on colorectal  
cancer-specific mortality of diabetic  
colorectal cancer patients**

Jung Won Park

Department of Medicine

The Graduate School, Yonsei University

# **Gender-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients**

Directed by Professor Tae Il Kim

The Master's Thesis submitted to the Department of  
Medicine

The Graduate School of Yonsei University College  
In partial fulfillment of the requirements for the  
degree of Master of Medical Science

**Jung Won Park**

December 2016

This certifies that the Master's Thesis  
of Jung Won Park is approved.

---

Thesis Supervisor : Tae Il Kim

---

Thesis Committee Member #1 : Byung Wan Lee

---

Thesis Committee Member #2 : Kang Young Lee

The Graduate School  
Yonsei University

December 2016

## **Acknowledgements**

This dissertation could not have been completed without the great support that I have received from some people over few months. I wish to offer my most heartfelt thanks to the following people.

First of all, and greatest of all, I would like to express my deep appreciation to my supervisor Prof. Dr. Kim Tae Il for his valuable guidance, useful comments and remarks through the learning process of this master thesis. Without his considerate engagement, this work would not have been completed. It is not often that one finds a mentor who always finds a way to solve problems which seemed so hard to break at the time with such patience. His technical and editorial advice was essential to the completion of this dissertation and has taught me cherished insights on the workings of academic research in general.

My thanks go to my statistics advisor Mr. Noh Yoon Ho, who helped me out with statistical problems. His effort to find the right methods for my thesis to be productive and accurate was hugely touching and memorable, and his

counsels were truly useful and consolable.

I would also like to thank my Mother who always supported my decisions and works from childhood, who knows me best and always gives me motivations. Her emotional support helped me a lot though the whole process. Moreover, the friendship of Jung Eun Lee is much appreciated and has led to many interesting and good-spirited discussions relating to this research. Her strong encouragement led me to complete the thesis finally.

## <TABLE OF CONTENTS>

Abstract .....	1
I.    Introduction .....	2
II.   Patients and methods .....	4
1. Patients .....	4
2. Tumor staging and treatment assessment .....	6
3. Statistical Analysis .....	6
III.  Results .....	8
1. Patient's demographics and clinical characteristics .....	8
2. Metformin use and survival analysis .....	8
3. Interaction analysis of survival benefit from metformin treatment .....	13
IV.  Discussion .....	16
References .....	22
Abstract In Korean .....	27

## LIST OF FIGURES

Figure 1. Flow chart of enrolled patients .....	5
Figure 2. CRC-specific survival and overall survival according to metformin treatment in DM patients with CRC. ....	11
Figure 3. CRC-specific survival based on sex. ....	15

## LIST OF TABLES

Table 1. Patient demographics and baseline clinical characteristics .....	9
Table 2. Multivariate logistic regression analysis for CRC-specific mortality .....	12
Table 3. Interaction analysis of metformin and relevant factors on CRC-specific mortality .....	13

## ABSTRACT

### **Gender-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients**

Jung Won Park

Department of Medicine

The Graduate School, Yonsei University

(Directed by Professor Tae Il Kim)

**Background:** Previous studies showed metformin use was associated with decreased colorectal cancer(CRC) mortality. However, the factors related to the effectiveness of metformin have not been identified. This study assessed factors associated with the effect of metformin on mortality in diabetic CRC patients.

**Methods:** Between January 2000 and December 2010, 413 patients diagnosed with both stage 3/4 CRC and diabetes mellitus(DM) were identified. Patients' demographics and clinical characteristics were analyzed. The effect of metformin on CRC-specific mortality and the interactions between metformin and each adjusted factor were evaluated.

**Results:** Total follow-up duration was median 50 months(range: 1–218 months). In multivariate analysis, survival benefit associated with metformin administration was identified(HR=0.985, 95% CI 0.974–0.997,  $p=0.012$ ). Interaction test between metformin and sex after adjustment for relevant factors revealed that female CRC patients taking metformin exhibited a significantly lower CRC-specific mortality rate than male CRC patients taking metformin(HR=0.369, 95% CI 0.155–0.881,  $p=0.025$ ). Furthermore, subgroup analysis revealed significant differences in CRC-specific mortality between the metformin and non-metformin groups in female

patients(HR=0.501, 95% CI 0.286–0.879,  $p=0.013$ ) but not male patients(HR=0.848, 95% CI 0.594–1.211,  $p=0.365$ ). There were no significant interactions between metformin and other adjusted factors on CRC-specific mortality.

**Conclusion:** We showed a strong gender-dependent difference in the effect of metformin on CRC-specific mortality in advanced stage CRC patients with diabetes.

---

Key words: Colorectal cancer, Metformin, Survival, Gender

## I. Introduction

Although the survival rate for colorectal cancer (CRC) has increased because of early detection and intervention at earlier stages, CRC is still the third most common cancer and the fourth leading cause of cancer death in the western and Asian countries.<sup>1-3</sup> Cancer and diabetes, especially type 2 diabetes mellitus (DM), are two of the most prevalent diseases and major causes of morbidity and mortality worldwide.<sup>4</sup> Despite some argument concerning the influence of diabetes on CRC, studies including meta-analyses consistently have demonstrated that type 2 DM is an independent risk factor for CRC and that diabetic patients with CRC have worse outcomes than non-diabetics.<sup>4,5</sup> A possible role for anti-hyperglycemic medications in progression and prognosis of CRC has been suggested, based on the hypothesis that tumor growth is promoted by the trophic action of insulin.<sup>4,6</sup>

Metformin is broadly used for the treatment of type 2 DM, which successfully decreases circulating levels of glucose and insulin mainly by improving insulin resistance. Evidence from preclinical studies has identified the anti-tumor effect of metformin, showing inhibition of tumor growth and induction of apoptosis in cell lines and animal models of various cancers.<sup>7-9</sup> Several clinical studies, including our previous study,<sup>10-18</sup> have shown the ability of metformin to reduce the incidence of CRC and improve survival of CRC patients. As stated in other studies, one of the potential mechanisms of the anti-tumor effect of metformin is via activation of AMP-activated protein kinase (AMPK). AMPK activation has an inhibitory effect on cancer cell growth and new blood vessel formation by prohibiting activation of the mammalian target of rapamycin (mTOR).<sup>19-21</sup> With these direct cellular effects of metformin, the indirect or systemic effect of metformin is relief of insulin resistance-associated hyperinsulinemia and hyperglycemia, which counteracts the dependence of cancer cells on glucose as predominant source of energy.<sup>20,22</sup>


Despite substantial evidence from *in vivo* and *in vitro* research supporting the possible efficacy of metformin as an anti-cancer agent and numerous clinical studies investigating the effect of metformin on CRC, particular factors or specific groups of patients associated with the effectiveness of metformin have not been identified. Our study assessed factors that may affect the efficacy of the anti-cancer action of metformin on CRC-specific mortality in diabetic CRC patients. Herein, we selected particular factors that might be associated with the ‘more effective’ group: those who benefit from metformin for improving CRC-specific survival, and verified these assumptions using interaction analysis.

## **II. Patients and Methods**

### **1. Patients**

The electronic records of 9,472 consecutive patients with a diagnostic code of colon or rectal cancer seen at a single institution (Severance Hospital, Yonsei University, Seoul, Korea) between January 1, 2000 and December 31, 2010 were identified. A manual retrospective review was conducted for all patients to identify those with a prior history of diabetes mellitus (DM). Among those identified, 1,584 had the type 2 diabetes diagnostic code during follow-up; 790 were excluded based on the following exclusion criteria: type I diabetes (12), diabetes diagnosed after CRC diagnosis (521), incomplete records (including medication records) (103), metformin use for less than 6 months (105), and any cancer previous to CRC diagnosis (49). According to our previous studies, only stage 3 CRC patients<sup>12</sup> and resectable stage 4 CRC patients<sup>23</sup> showed a survival benefit from metformin. Considering these results, advanced stage CRC patients in the latter two groups, denoting stage 3 and 4 patients, were selected and analyzed: 185 DM patients treated with metformin and 228 DM patients not taking metformin. There were 135

female patients (32.7%) in the study population.



**Figure 1.** Flow chart of enrolled patients

Patient demographics and clinical characteristics, including age at diagnosis, gender, total follow-up duration, duration of diabetes, body mass index (BMI), family history of colorectal malignancy, smoking history, drinking history were obtained from medical records. Body mass index was stratified into ‘underweight’ (BMI < 18.5), ‘normal’ (BMI range: 18.5 – 24.9), ‘overweight’ (BMI range: 25.0 – 29.9), and ‘obese’ (BMI ≥ 30.0) based on WHO (World Health Organization) BMI classification.<sup>24</sup> Laboratory findings included plasma glucose levels, glycated hemoglobin (HbA1C) levels, and pretreatment carcinoembryonic antigen (CEA) levels. Information relevant to the CRC diagnosis, such as stage, site, histology, differentiation, resection margin, lymphovascular invasion, microsatellite instability

(MSI) status, and treatment modality were reviewed via the medical records as well. The use of other diabetes medications (sulfonylureas, thiazolidinediones,  $\alpha$ -glucosidase inhibitors, insulin, etc.) and the use of aspirin were also explored. The date of diagnosis of CRC was defined as the day of pathologic diagnosis. Every enrolled patient had undergone colonoscopy. We identified deaths through medical records, and determined the cause of death in all cases.

The institutional review board of Severance Hospital, Yonsei University, Seoul, Korea approved this study.

## **2. Tumor staging and treatment assessment**

All patients were diagnosed with pathologically confirmed CRC and were evaluated during their baseline visit to Severance Hospital for appropriate staging according to 7<sup>th</sup> version of the AJCC Tumor/Node/Metastatic (TNM) staging system. Treatment modality was determined by extent and location of the tumor. Based on the National Comprehensive Cancer Network (NCCN) guideline, locally advanced tumors or advanced tumors with resectable metastatic lesions were treated by surgery followed by adjuvant chemotherapy with or without radiotherapy, or by neoadjuvant chemotherapy, or chemoradiation therapy followed by surgery. Advanced CRC with distant metastasis was treated by palliative chemotherapy or conservative care.

## **3. Statistical Analysis**

Differences between the metformin and non-metformin groups with regard to covariates were determined using Pearson's chi-square test or Student's t-test when the data were categorical or continuous, respectively. In the primary analyses, the odds of overall and CRC-specific death for patients with diabetes treated with metformin and not treated with metformin were calculated using univariate logistic

regression analysis. The multivariate Cox proportional hazards regression method was used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) after adjustment for patient-related variables, including age at diagnosis, sex, stage of cancer, BMI, diabetes duration, smoking history, cancer site, use of insulin, aspirin, sulfonylurea, and thiazolidinedione. Survival curves were generated using the Kaplan-Meier method and were compared using log-rank statistics. In the secondary analyses, interaction analyses of Cox regression results were performed to reveal the factors associated with metformin use. These variables included age at diagnosis ( $\geq 50$  or  $< 50$ ), sex (male or female), smoking history (yes or no), tumor stage (III or IV), site (colon or rectum), sulfonylurea use (yes or no), insulin use (yes or no), and DM duration (years). All  $p$  values were two sided, with a  $p < 0.05$  considered significant. Most of the statistical analyses were performed using SPSS version 21.0 (SPSS, Inc., Chicago, IL, USA). SAS version 9.2 (SAS Inc., Cary, NC, USA) was used when identifying the cut-off value of metformin duration that provided the best fit of the log-rank test statistics of overall and CRC-specific survival.

### III. Results

#### 1. Patients' demographics and clinical characteristics

The metformin and non-metformin groups had similar patient demographics and clinical characteristics (Table 1). The median age of patients was 64 years (range 33–91 years). Baseline characteristics including age at diagnosis, sex, BMI, familial history of cancer, smoking and drinking history and co-morbidities were not significantly different between the metformin group and the non-metformin group. Factors associated with cancer, including tumor stage, tumor site (colon or rectum), tumor differentiation, resection margin positivity, MSI status, and pretreatment CEA level were not significantly different between the two groups. Clinical characteristics associated with diabetic severity status, such as HbA1C levels and duration of diabetes, were similar between the two groups; however, serum fasting glucose levels were lower in the non-metformin group compared to the metformin group (143.8 mg/dL vs 132.4 mg/dL;  $p=0.012$ ). The use of other diabetes medications, including insulin, sulfonylurea, and thiazolidinedione was also investigated, because the status of individuals taking these medications could reflect later stage diabetes, and these medications could be associated with tumorigenesis and prognosis. The use of these medications was not significantly different between the two groups, with the exception of insulin use, which was lower in the metformin group than in the non-metformin group (9.2% vs 16.2%,  $p=0.035$ ). Aspirin, a drug known to have beneficial effects in cancer survival, also was evaluated and its use was statistically different between two groups (27.0% vs 17.1%,  $p=0.015$ ). Meanwhile, there was no difference in the treatment modality used for CRC between the two groups.

#### 2. Metformin use and survival analysis

The median follow-up duration was 50 months (range 1–180 months). With


respect to the entire cohort, there were 129 (31.3%) recurrences, 215 (52.0%) total deaths, and 179 (43.3%) CRC-specific deaths. With respect to metformin use, there were 85 (45.9%) total deaths and 72 (38.9%) CRC-specific deaths among 185 patients who used metformin, compared with 130 (57.0%) total deaths and 107 (46.9%) CRC-specific deaths among 228 patients who did not use metformin. The estimated 5-year CRC-specific survival rates were 65.4% and 52.4% for the metformin and non-metformin groups, respectively, and 10-year CRC-specific survival rates were 50.8% and 43.1%, respectively. These results were significantly different (HR=0.724; 95% CI 0.537–0.976;  $p=0.032$ ) (Fig. 2a). For the metformin and non-metformin groups, the estimated 5-year overall survival rate was 60.8% and 47.9% respectively, and the 10-year overall survival rate was 45.8% and 33.8% respectively, which also was significantly different (HR=0.706; 95% CI 0.537–0.929;  $p=0.013$ ) (Fig. 2b).

**Table 1. Patient demographics and baseline clinical characteristics**


	Metformin (n=185)	group	Non-metformin (n=228)	group	<i>p</i> value
<b>Age at diagnosis (mean±SD) years</b>	63.5 ± 8.789		63.49 ± 10.218		0.991
< 50 years	12 (6.5%)		27 (11.8%)		0.064
≥50 years	173(93.5%)		201 (88.2%)		
<b>Sex</b>					0.921
Male	125 (67.6%)		153 (67.1%)		
Female	60 (32.4%)		75 (32.9%)		
<b>DM duration (median), years</b>	8 (1-120)		6 (1-40)		0.068
<b>Family history of CRC</b>	8 (4.3%)		13 (5.7%)		0.526
<b>Comorbidities</b>					
Cardiovasculr disease	40 (21.6%)		43 (18.8%)		0.305
Hepatitis	3 (1.6%)		4 (1.8%)		0.705
Pulmonary tuberculosis	2 (1.0%)		2 (0.9%)		0.582
<b>BMI (mean±SD), kg/m<sup>2</sup></b>	23.6 ± 3.0		23.5 ± 3.0		0.596
Normal (<25)	148 (80.0%)		173 (76.5%)		0.3
Overweight (25–30)	33 (17.8%)		51 (22.6%)		
Obese (≥30)	4 (2.2%)		2 (0.9%)		
<b>Smoking</b>					0.371
Never-smoker	89 (48.1%)		123 (53.9%)		
Ex-smoker	42 (22.7%)		40 (17.5%)		
Current smoker	54 (29.2%)		65 (28.5%)		

<b>Alcohol</b>			0.556
None	82 (44.3%)	112 (49.1%)	
<1 drink/day	42 (22.7%)	51 (22.4%)	
≥1 drink/day	61 (33.0%)	65 (28.5%)	
<b>Aspirin use</b>	50 (27.0%)	39 (17.1%)	0.015
<b>Insulin use</b>	17 (9.2%)	27 (16.2%)	0.035
<b>Sulfonylurea use</b>	116 (62.7%)	153 (67.1%)	0.35
<b>Thiazolidinedione use</b>	18 (9.7%)	12 (5.3%)	0.082
<b>CEA (medina, range), ng/ml</b>	4.7 (0.2-9100.0)	6.4 (0.1-5946.0)	0.359
<b>HbA1c ± SD (%)</b>	8.7 ± 16.7	7.3 ± 1.4	0.349
<b>Glucose, AC ± SD (mg/dl)</b>	143.8 ± 46.1	132.4 ± 41.1	0.012
<b>Cholesterol, total ± SD (mg/dl)</b>	167.9 ± 47.8	164.6 ± 39.6	0.483
<b>Tumor stage</b>			0.11
III	136 (73.5%)	151 (66.2%)	
IV	49 (26.5%)	77 (33.8%)	
<b>Tumor site</b>			0.94
Colon	106 (57.9%)	130 (58.3%)	
Rectum	77 (42.1%)	93 (41.7%)	
<b>Histology</b>			0.001
Adenocarcinoma	177 (97.8%)	199 (89.6%)	
Mucinous carcinoma	4 (2.2%)	23 (10.4%)	
<b>Differentiation</b>			0.155
Well differentiated	13/175 (7.4%)	16/206 (7.8%)	
Moderately differentiated	148/175 (84.6%)	174/206 (84.5%)	
Poorly differentiated	14/175 (8.0%)	12/206 (5.8%)	
<b>Resection margin (+)</b>	3/161 (1.7%)	1/180 (0.6%)	0.371
<b>Lymphovascular invasion</b>	56/152 (25.9%)	76/156 (50.0%)	0.031
<b>MSI state</b>			0.67
MSS	78/87 (89.7%)	68/75 (90.7%)	
MSI-low	6/87 (6.9%)	6/75 (8.0%)	
MSI-high	3/87 (3.4%)	1/75 (1.3%)	
<b>Treatment modality</b>			0.160
Resection only	9 (4.9%)	20 (8.8%)	
Resection + adjuvant chemotherapy	115 (63.2%)	126 (55.3%)	
Resection + chemoradiotherapy	22 (12.1%)	24 (10.5%)	
Neoadjuvant chemotherapy + resection	17 (9.3%)	17 (7.5%)	
Chemotherapy only	17 (9.3%)	35 (15.4%)	
Conservative care	2 (1.1%)	6 (2.6%)	

(a)



(b)



**Figure 2.** CRC-specific survival and overall survival according to metformin treatment in CRC patients with DM. (a) CRC-specific survival according to metformin treatment. (b) Overall survival according to metformin treatment.

In addition, we used the duration of metformin treatment in multivariate survival analysis, and showed this factor to be an independent predictor for CRC-specific mortality in diabetic patients with advanced CRC after adjustment of clinically relevant factors (HR=0.985; 95% CI 0.974–0.992;  $p=0.012$ ). BMI (HR 0.514; 95% CI 0.287–0.919;  $p=0.025$ ), tumor stage (HR=8.401; 95% CI 5.285–13.355;  $p<0.001$ ), and HbA1C level (HR=1.015; 95% CI 1.004–1.027;  $p=0.01$ ) were also revealed as independent predictive factors (Table 2).

**Table 2. Multivariate logistic regression analysis for CRC-specific mortality**

	<b>Hazard ratio</b>	<b>95% CI</b>	<b><i>p</i> value</b>
<b>Age at diagnosis (<math>\geq 50</math> or <math>&lt;50</math>)</b>	0.723	0.312–1.675	0.449
<b>Sex (female or male)</b>	0.592	0.357–0.982	0.042
<b>BMI (<math>\geq 25</math> or <math>&lt;25</math>)</b>	0.514	0.287–0.919	0.025
<b>Smoking history (yes or no)</b>	0.681	0.359–1.291	0.239
<b>Aspirin use (yes or no)</b>	0.802	0.455–1.415	0.446
<b>Metformin treatment duration (months)</b>	0.985	0.974–0.997	0.012
<b>Sulfonylurea use (yes or no)</b>	1.300	0.798–2.12	0.292
<b>Insulin use (yes or no)</b>	1.041	0.511–2.121	0.912
<b>Stage (IV or III)</b>	8.401	5.285–13.355	$<0.001$
<b>Site (rectum or colon)</b>	0.823	0.521–1.299	0.403
<b>Differentiation (Differentiated or de-differentiated)</b>	0.801	0.238–2.701	0.721
<b>Diabetes duration (months)</b>	0.968	0.935–1.001	0.059
<b>HbA1C (%)</b>	1.015	1.004–1.027	0.01

CI: confidence interval; BMI: body mass index; CRC: colorectal cancer.

We performed another analysis with the metformin group only, using total duration of metformin treatment. The results showed that improvement of CRC-specific (HR=0.976; 95% CI 0.948–0.995;  $p=0.012$ ) and overall survival rates (HR=0.982; 95% CI 0.967–0.997;  $p=0.019$ ) was associated with longer duration of

metformin treatment, after adjustment of clinically relevant factors including age at diagnosis, sex, medication history, tumor stage, tumor site, diabetes duration, and HbA1C. Analysis using Contal and O’Quigley’s method<sup>25</sup> revealed the cutoff value for metformin treatment duration that fit the CRC-specific survival statistics was 22 months.

### 3. Interaction analysis of survival benefit from metformin treatment

To determine the subgroup with the greater metformin effect, interaction tests between metformin and each clinical factor were performed, after adjustment for other covariates including age at diagnosis, sex, BMI, medication use, stage, site, diabetes duration, and HbA1C. Interaction tests between metformin and sex with adjustment for relevant factors revealed that female CRC patients treated with metformin exhibited a significantly lower CRC-specific mortality rate compared to male CRC patients treated with metformin (HR=0.369; 95% CI 0.155–0.881;  $p=0.025$ ) (Table 3). Subgroup analysis based on sex was performed and showed a significant difference in CRC-specific mortality between metformin and non-metformin group for females (HR=0.013; 95% CI 0.286–0.879;  $p=0.013$ ) (Fig. 3b), while there was no significant difference between the two groups for males (HR=0.365; 95% CI 0.594–1.211;  $p=0.365$ ) (Fig. 3a).


**Table 3. Interaction analysis of metformin and relevant factors on CRC-specific mortality**

	Hazard ratio	95% CI	<i>p</i> value
<b>Metformin * Sex</b>	0.369	0.155–0.881	0.025
<b>Metformin * BMI</b>	1.000	0.974–1.026	0.972
<b>Metformin * Site</b>	0.941	0.441–2.006	0.875
<b>Metformin * HbA1c</b>	0.999	0.926–1.078	0.979

CI: confidence interval; BMI: body mass index; CRC: colorectal cancer.

Interaction analysis of metformin with other adjusted factors did not show any significant difference in CRC-specific mortality (Table 3). Intriguingly, as

documented earlier, the duration of metformin treatment affected both CRC-specific mortality and overall mortality; however, the mean duration of metformin treatment between males and females was not significantly different ( $33.76 \pm 24.45$  months for males and  $28.05 \pm 20.59$  for females, log rank  $p=1.06$ ). Subgroup analysis based on metformin treatment showed that female patients had significantly lower CRC-specific mortality than males in the metformin group (HR=0.332; 95% CI 0.144–0.764;  $p=0.009$ ), while the non-metformin group showed no significant difference in CRC-specific mortality between male and female patients (HR=0.73; 95% CI 0.38–1.402;  $p=0.345$ ).



**Figure 3.** CRC-specific survival based on sex. (a) CRC-specific survival according to metformin treatment in males. (b) CRC-specific survival according to metformin treatment in females.

#### IV. Discussion

Two of the most common diseases worldwide, DM and CRC, share numerous risk factors. Previous studies including meta-analyses demonstrated the association between DM and increased risk of CRC; moreover, metformin, one of the most commonly prescribed anti-diabetes agents, improved survival of CRC patients.<sup>11,12,14,16,18</sup> We previously showed that CRC patients with diabetes treated with metformin had lower mortality than those not treated with metformin, and that metformin treatment was associated with a decreased incidence of colorectal adenomas in diabetic patients with previous CRC.<sup>12,26</sup> Furthermore, we showed an association between the metformin treatment in stage IV CRC patients with diabetes and lower risk of tumor recurrence after curative resection.<sup>23</sup> However, there has been no study that investigated the specific subgroup within CRC patients with diabetes who obtained a survival benefit from metformin use. In the present study, we aimed to determine the particular subgroup among diabetic CRC patients that could benefit from the anti-cancer effect of metformin and discovered that sex was the single clinical factor that predicted improved survival related to metformin treatment. In addition, by including the duration of metformin treatment as a factor, we showed that longer duration of metformin treatment was associated with improved CRC-specific and overall survival.

Metformin treatment has been associated with decreased risk and improved survival of DM patients with various types of cancer, including colorectal, pancreatic, liver, ovarian, breast, and endometrial.<sup>11,18</sup> The mechanism of action of metformin as an anti-cancer drug has not been clearly identified, although a shared pathogenesis for DM and some cancers is possible, e.g., beta oxidation of fatty acids or mitochondrial function.<sup>22</sup> One of the most well-known mechanisms of metformin is the stimulation of peripheral AMP-activated protein kinase (AMPK) with decreased hepatic gluconeogenesis, increased insulin sensitivity, and hepatic fatty

acid oxidation.<sup>20</sup> Under physiological conditions, AMPK is an intracellular energy sensor and is activated when the cellular AMP/ATP ratio increases. AMPK activation leads to inhibition of mTOR signaling. mTOR phosphorylation is mainly involved in cell growth, cell cycle progression, and angiogenesis. Inhibition of mTOR signaling can be an excellent cancer therapy target, as the mTOR pathway is commonly decontrolled in numerous types of cancer, and activation of this pathway is associated with poor prognosis and resistance to chemotherapy.<sup>21,27,28</sup> Other suggested anti-cancer mechanisms of metformin include reduced insulin growth factor (IGF)-1, inhibition of angiogenesis, apoptosis, and induction of cell cycle arrest.<sup>6,29,30</sup>

In our study population, females had a higher survival rate associated with metformin treatment after adjustment of other clinically significant factors. No other studies have reported the interaction between sex and survival benefit from metformin in diabetics with CRC. However, the study by Lee et al. of a cohort of 800,000 Taiwanese showed that metformin effectively reduced the incidence of CRC in diabetic women and liver cancer in diabetic men, which suggested that sex could be an important interaction factor.<sup>18</sup> Numerous explanations for this phenomenon can be suggested, and the higher survival rate of females compared to males among patients with CRC should initiate additional studies. A Japanese study of 82,402 patients with invasive CRC who had undergone surgery between 1985 and 2004 revealed a reduced risk of CRC-specific death for females relative to males that persisted over time.<sup>31</sup> McArdle et al. reported that overall survival and CRC-specific survival was significantly higher in females among patients who underwent elective surgery, after adjustment of clinical covariates.<sup>32</sup> One study conducted in Israel by Purim et al. also reported sex-age interactions with the incidence of CRC and survival of CRC patients showed lower incidence and better prognosis for females.<sup>33</sup> The answer for this superior CRC survival in females

compared to males is usually related to female sex hormone status, particularly serum estrogen levels.<sup>31,34,35</sup> Circulating levels of 17 $\beta$ -estradiol (E2), the main estrogenic compound, are exceedingly higher in females compared to males and decrease with increasing age. While females are exposed to relatively high levels of endogenous E2 between adolescence and the fourth or fifth decade of life, in males, E2 levels remain low and steady, and drop minimally with aging. However, after menopause, serum E2 levels of females decline to levels similar to those of males. Moreover, the effect of estrogen on the gastrointestinal tract is well known, and in esophageal, gastric, and colon cancers, which have higher incidence and mortality rates among males, the role of estrogen has been investigated.<sup>36,37</sup> Wang et al. reported that people with at risk of esophageal cancer have low levels of estrogen compared to healthy subjects. This finding was supported by experimental studies showing that estrogen regulates growth, cell differentiation, and cell function in the gastrointestinal tract.<sup>38</sup> The possible role of estrogen in CRC development has been suggested by several lines of epidemiological, clinical, and experimental evidence; however, the effect of estrogen in the progression of CRC has not been clearly identified.<sup>37,39</sup>

With respect to metformin and female hormones, we hypothesized that metformin acts on the estrogen pathway to affect progression of CRC. This can be inferred from another result of Cossor et al., showing no significant survival benefit of metformin in post-menopausal females.<sup>40</sup> Reports of the anti-cancer effect of metformin in estrogen receptor (ER)-positive breast cancer and the anti-estrogenic effect of metformin in control of abnormal endometrial proliferative disorders support this hypothesis.<sup>41,42</sup> The decrease in ER expression in tumors from females with endometrial cancer and DM treated with metformin compared to women treated with insulin also supports this hypothesis.<sup>42</sup> In addition, metformin repressed protein and mRNA expression of E2/ER $\alpha$ -regulated genes to a greater degree than

tamoxifen, which resulted in inhibition of cell proliferation of ER $\alpha$ -positive breast cancer cells.<sup>41</sup> Interestingly, estrogen (E2) primarily prevented the development of CRC; however, in CRC patients, E2 promoted cancer progression.<sup>43</sup> Proliferation of colorectal cancer cells is known to be mediated by ER $\alpha$ , while the level of ER $\alpha$  expression is usually low in normal colon tissue and colorectal cancer tissue.<sup>43</sup> However, when the expression of ER $\beta$  in cancer cells decreases and the ratio of ER $\alpha$ /ER $\beta$  rises, ER $\alpha$  expression becomes dominant and results in cell proliferation and inhibition of apoptosis.<sup>43,44</sup> Interestingly, studies have demonstrated sex differences in ER expression in CRC.<sup>44,45</sup> Nussler et al. reported a significant increase in ER $\alpha$  protein expression in males but not in females, while there was no significant difference in ER $\alpha$  and ER $\beta$  protein in normal colon mucosa between males and females.<sup>44</sup> In the same study, ER $\beta$  protein expression in CRC cells was significantly decreased in both males and females, but far more in males.<sup>44</sup> Another study conducted by Press et al. reported the correlation between ER $\beta$  protein expression in CRC cells, overall survival and sex.<sup>45</sup> Higher ER $\beta$  protein expression was associated with better overall survival in females but worse survival in males.<sup>45</sup> From these reports, we inferred that ER status in colorectal cancer tissue might have a role in cancer progression that could be different between males and females. The effect of metformin might be related to estrogen, regulation of ER $\alpha$  or ER $\beta$  expression, or, possibly, E2/ER $\alpha$  ratio as well. Although these relationships have not been elucidated thus far, we postulate that our findings provide the basis for future studies.

As confounding factors, DM severity and treatment with other drugs could affect the survival benefit conferred by metformin. Severity and duration of DM are important factors for cancer progression, considering that persistent hyperglycemia and hyperinsulinemia might alter the immune system and cause a chronic pro-inflammatory condition.<sup>4,5</sup> This pathologic state is due to the metabolic

abnormalities that characterize diabetes, especially under conditions of poor metabolic control. In the present study, we measured glycated hemoglobin to represent the severity of DM, and total duration since diagnosis of DM. In addition, other anti-hyperglycemic agents may conceal or diminish this metformin-related cancer protection. Therefore, we adjusted DM severity and duration, along with other anti-hyperglycemic agents, to assess the dose-dependent survival benefit of metformin. Several studies have investigated the relationship between metformin duration or dosage-related numerical values and the incidence of CRC. While there are some discrepancies between the study results, one study showed that patients treated with metformin for over 3 years showed a significantly reduced relative risk of CRC (HR: 0.643; 95% CI 0.490–0.845) compared to patients not treated with metformin.<sup>46</sup> Interestingly, Lee et al. demonstrated that total cancer incidence was significantly associated with mean daily dose of metformin.<sup>18</sup> Furthermore, subgroup analysis of males and females showed other intriguing results; only the hazard ratio of liver cancer incidence was significantly associated with mean daily dose of metformin in males while CRC incidence was significantly associated with mean daily dose in females.<sup>18</sup> Our study results showed the relationship between the cumulative effect of metformin and CRC-specific survival. In addition, duration of DM since diagnosis, duration of metformin treatment, and level of glycated hemoglobin were not significantly different between males and females, which showed that the severity of DM or months of metformin treatment had no effect on the sex-related interaction.

While this study provided notable associations between metformin treatment and sex in the survival of CRC patients with DM, there were some limitations. First, we could not capture metformin treatment noncompliance, which could have resulted in exposure misclassification and biased the results toward the null hypothesis. Additional study limitations included a small sample size, which reduced the power

to detect significant differences in survival, even though our findings were similar to previous studies of metformin treatment and CRC outcomes. Data regarding the specific cancer location, such as right or left sided, were not available for this study. Location of cancer is an important difference between males and females, where females develop more proximal, and males more distal colon and rectal cancers.<sup>47,48</sup> Finally, because the data analyzed in this study population were collected from a tertiary medical care unit, results may not be generalizable to the general population. Further studies with a larger and more diverse population should be conducted to strengthen the relationship between sex and the anti-cancer effect of metformin in CRC patients with DM. Moreover, future prospective studies should consider this sex-specific difference when performing clinical trials using metformin as an additive therapeutic agent for diabetic and non-diabetic CRC patients.

**Grants:** This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2013R1A1A2010733), and a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1631020).

## References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015;65:5-29.
2. Lim D, Ha M, Song I. Trends in major cancer mortality in Korea, 1983-2012, with a joinpoint analysis. *Cancer Epidemiol* 2015;39:939-46.
3. Sung JJ, Lau JY, Goh KL, Leung WK. Increasing incidence of colorectal cancer in Asia: implications for screening. *Lancet Oncol* 2005;6:871-6.
4. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. *Endocr Relat Cancer* 2009;16:1103-23.
5. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. *Am J Epidemiol* 2004;159:1160-7.
6. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. *Nat Rev Cancer* 2008;8:915-28.
7. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. *Endocr Relat Cancer* 2010;17:351-60.
8. Bojkova B, Orendas P, Garajova M, Kassayova M, Kutna V, Ahlerova E, et al. Metformin in chemically-induced mammary carcinogenesis in rats. *Neoplasma* 2009;56:269-74.
9. Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. *Mol Carcinog* 2010;49:662-71.
10. Singh S, Singh H, Singh PP, Murad MH, Limburg PJ. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2013;22:2258-68.
11. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. *Cancer Epidemiol* 2013;37:207-18.
12. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin

- on the survival of colorectal cancer patients with diabetes mellitus. *International Journal of Cancer* 2012;131:752-9.
13. Fransgaard T, Thygesen LC, Gogenur I. Metformin Increases Overall Survival in Patients with Diabetes Undergoing Surgery for Colorectal Cancer. *Ann Surg Oncol* 2015; doi:10.1245/s10434-015-5028-8.
  14. Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab* 2014;16:707-10.
  15. Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. *Diabetes Care* 2011;34:2323-8.
  16. Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. *Br J Cancer* 2012;106:1374-8.
  17. Lin JJ, Gallagher EJ, Sigel K, Mhango G, Galsky MD, Smith CB, et al. Survival of patients with stage IV lung cancer with diabetes treated with metformin. *Am J Respir Crit Care Med* 2015;191:448-54.
  18. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. *BMC Cancer* 2011;11:20.
  19. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. *J Biol Chem* 2000;275:223-8.
  20. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab* 1996;81:4059-67.
  21. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest* 2001;108:1167-74.
  22. Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E, Schwab M. Metformin and

- cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. *Trends Pharmacol Sci* 2013;34:126-35.
23. Lee DJ, Kim B, Lee JH, Park SJ, Hong SP, Cheon JH, et al. [The effect of metformin on responses to chemotherapy and survival in stage IV colorectal cancer with diabetes]. *Korean J Gastroenterol* 2012;60:355-61.
  24. Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 2004;363:157-63.
  25. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. *Computational Statistics & Data Analysis* 1999;30:253-70.
  26. Lee JH, Jeon SM, Hong SP, Cheon JH, Kim TI, Kim WH. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. *Dig Liver Dis* 2012;44:1042-7.
  27. Wang XW, Zhang YJ. Targeting mTOR network in colorectal cancer therapy. *World J Gastroenterol* 2014;20:4178-88.
  28. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. *BMC Med* 2011;9:33.
  29. Rozengurt E, Sinnott-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. *Clin Cancer Res* 2010;16:2505-11.
  30. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. *Cancer Res* 2010;70:2465-75.
  31. Kotake K, Asano M, Ozawa H, Kobayashi H, Sugihara K. Gender differences in colorectal cancer survival in Japan. *Int J Clin Oncol* 2015; doi:10.1007/s10147-015-0868-6.
  32. McArdle CS, McMillan DC, Hole DJ. Male gender adversely affects survival following surgery for colorectal cancer. *Br J Surg* 2003;90:711-5.
  33. Purim O, Gordon N, Brenner B. Cancer of the colon and rectum: potential effects of sex-age interactions on incidence and outcome. *Med Sci Monit* 2013;19:203-9.

34. Wichmann MW, Muller C, Hornung HM, Lau-Werner U, Schildberg FW, Colorectal Cancer Study G. Gender differences in long-term survival of patients with colorectal cancer. *Br J Surg* 2001;88:1092-8.
35. Kim HM, Kim H-S. Gender-specific Colorectal Cancer: Epidemiologic Difference and Role of Estrogen. *The Korean Journal of Gastroenterology* 2014;63:201.
36. Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. *Gut* 2009;58:16-23.
37. Singh S, Langman MJ. Oestrogen and colonic epithelial cell growth. *Gut* 1995;37:737-9.
38. Wang QM, Yuan L, Qi YJ, Ma ZY, Wang LD. Estrogen analogues: promising target for prevention and treatment of esophageal squamous cell carcinoma in high risk areas. *Med Sci Monit* 2010;16:Hy19-22.
39. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. *Am J Med* 1999;106:574-82.
40. Cossor FI, Adams-Campbell LL, Chlebowski RT, Gunter MJ, Johnson K, Martell RE, et al. Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. *Cancer Epidemiology* 2013;37:742-9.
41. Kim J, Lee J, Jang SY, Kim C, Choi Y, Kim A. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines. *Oncol Rep* 2016; doi:10.3892/or.2016.4675.
42. Markowska A, Pawalowska M, Filas V, Korski K, Grybos M, Sajdak S, et al. Does Metformin affect ER, PR, IGF-1R, beta-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer? *Diabetol Metab Syndr* 2013;5:76.
43. Barzi A, Lenz AM, Labonte MJ, Lenz HJ. Molecular pathways: Estrogen pathway in colorectal cancer. *Clin Cancer Res* 2013;19:5842-8.
44. Nussler NC, Reinbacher K, Shanny N, Schirmeier A, Glanemann M, Neuhaus P, et al. Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. *Gend Med* 2008;5:209-17.

45. Press OA, Zhang W, Gordon MA, Yang D, Haiman CA, Azuma M, et al. Gender-related survival differences associated with polymorphic variants of estrogen receptor-beta (ERbeta) in patients with metastatic colon cancer. *Pharmacogenomics J* 2011;11:375-82.
46. Tseng CH. Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. *Eur J Endocrinol* 2012;167:409-16.
47. Kim SE, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities in colorectal cancer risk. *World J Gastroenterol* 2015;21:5167-75.
48. Koo JH, Leong RW. Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer. *J Gastroenterol Hepatol* 2010;25:33-42.

## ABSTRACT (IN KOREAN)

### 배경 및 목적

Metformin은 경구 혈당 강하 제제 중 하나로 이전 연구들에서 결장직장암에서의 암 사망률 감소와 유의한 관련성이 있음이 보고되어 왔다. 그러나 metformin 의 이러한 효과와 연관된 특정 요인은 밝혀지지 않았으며, 따라서 본 연구에서는 당뇨를 가진 결장직장암 환자에서 metformin 의 암 사망률을 낮추는 데 기여하는 특정 요인을 찾고자 하였다.

### 대상 및 방법

2000년 1월부터 2010년 12월까지 연세대학교 세브란스 병원에서 결장직장암을 진단받은 환자 중 당뇨의 과거력이 있는 환자 794명을 대상으로 하였으며, 명확한 생존율의 차이를 위해 결장직장암 병기 3, 4 만을 포함하여 413명을 최종 대상으로 후향적으로 분석하였다. 이 중 185명의 metformin 복용자와 228명의 비복용자 각 군에서 metformin 사용여부에 따라 대상 환자의 임상적 특징 및 재발 여부, 생존율 등을 조사하여 비교하였다.

### 결과

총 추적 기간은 중간값(범위) 50개월(1-218)이었으며, metformin 복용군 185명 중 전체 사망 수 85명(45.9%), 암 특정 사망 수 72명(38.9%) 그리고 metformin 비복용군 228명 중 전체 사망 수 130명(57.0%), 암 특정 사망 수 107명(46.9%)이 확인되었다. 다변량 분석에서 metformin 복용군과 비복용군에서 암 생존율의 유의한 차이를 보였으며(HR=0.985, 95% CI 0.974-0.997,  $P=0.012$ ), 교호작용 검사(interaction test)에서는 ‘성별’이 metformin 의 생존율 향상 효과에 의미 있는 영향을 주는 것을 확인할 수 있었다. 그리고 여자에서 metformin 복용군이 남자에서 metformin 복용군에 비해 암 사망률이 유의미하게 감소하였다(HR=0.369, 95% CI 0.155-0.881,  $P=0.025$ ). 단변량 분석에서 여자 군에서는 metformin 투약 유무에 따라 암 사망률

의 유의한 차이를 보였지만(HR=0.501, 95% CI 0.286-0.879,  $P=0.013$ ), 남자 군에서는 그렇지 않았다(HR=0.848, 95% CI 0.594-1.211,  $P=0.365$ ). 다변량 교호작용 검사에서 metformin과 다른 요인들 사이에는 의미 있는 결과가 도출되지 않았다.

## 결론

당뇨를 가진 진행성 결장직장암 환자에서 “여성”의 성별이 metformin의 암 사망률을 낮추는 데 중요한 요인으로 작용함을 확인할 수 있었다.

---

핵심 되는 말 : 대장 직장암, 메트포민, 생존율, 성별